Showing results (51-60 of 84) with videos related to
Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 InstitutesCindy Varga, Myra Robinson, Vikas Gupta, et al.Current Oncology (Toronto, Ont.)|March 27, 2026
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter AnalysisSruthi P Ramanan, Oyepeju F Abioye, Shebli Atrash, et al.European Journal of Haematology|June 13, 2023
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myelomaShebli Atrash, Myra Robinson, Alankrita Taneja, et al.Ejhaem|July 18, 2022
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myelomaDavid M Foureau, Manisha Bhutani, Myra Robinson, et al.Cancers|November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed IntervalsJordan Snyder, Shebli Atrash, Barry Paul, et al.Current Oncology (Toronto, Ont.)|May 26, 2026
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible PatientsRaeef Rahman, Anas Zayad, Carmel Awadallah, et al.Clinical Lymphoma, Myeloma & Leukemia|October 26, 2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 TrialIshita Kamboj, Alma Habib, Darryl Chang, et al.Clinical Lymphoma, Myeloma & Leukemia|May 1, 2023
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First RelapseManisha Bhutani, David M Foureau, Myra Robinson, et al.Journal of Clinical Apheresis|March 12, 2021
Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantationSrinivasa Reddy Sanikommu, Emily S Reese, Jiaxian He, et al.Cancers|March 14, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC GroupMaha Hameed, Alma Habib, Abdullah Mohammad Khan, et al.Pageof 9